Barclays PLC Raises Holdings in HilleVax, Inc. (NASDAQ:HLVX)

Barclays PLC boosted its position in shares of HilleVax, Inc. (NASDAQ:HLVX) by 255.6% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 42,033 shares of the company’s stock after acquiring an additional 30,213 shares during the quarter. Barclays PLC owned about 0.08% of HilleVax worth $74,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of HLVX. Rhumbline Advisers grew its position in HilleVax by 27.0% during the second quarter. Rhumbline Advisers now owns 42,658 shares of the company’s stock valued at $617,000 after buying an additional 9,073 shares during the period. Fred Alger Management LLC boosted its holdings in HilleVax by 9.7% in the 2nd quarter. Fred Alger Management LLC now owns 136,166 shares of the company’s stock valued at $1,969,000 after purchasing an additional 12,044 shares during the last quarter. Maven Securities LTD purchased a new position in shares of HilleVax during the 2nd quarter worth $217,000. TD Asset Management Inc increased its position in shares of HilleVax by 53.9% during the second quarter. TD Asset Management Inc now owns 54,236 shares of the company’s stock valued at $784,000 after acquiring an additional 19,000 shares during the last quarter. Finally, BML Capital Management LLC acquired a new position in HilleVax during the third quarter worth $35,000. Hedge funds and other institutional investors own 86.42% of the company’s stock.

HilleVax Price Performance

NASDAQ HLVX opened at $2.09 on Friday. The company has a market cap of $104.09 million, a P/E ratio of -0.67 and a beta of 0.75. HilleVax, Inc. has a 1-year low of $1.55 and a 1-year high of $20.22. The stock has a 50-day moving average of $1.94 and a two-hundred day moving average of $2.68.

HilleVax (NASDAQ:HLVX) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.10). On average, analysts anticipate that HilleVax, Inc. will post -2.64 EPS for the current fiscal year.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.